Overview

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients

Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to assess the efficacy and safety of the combination of RAL+ATV/r in comparison with TDF/FTC+ATV/r in HIV-1 infected patients presenting virologic failure and PI and TDF naïve.
Phase:
Phase 4
Details
Lead Sponsor:
Pedro Cahn
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Atazanavir Sulfate
Lamivudine
Raltegravir Potassium
Ritonavir